GTG 7.14% 0.8¢ genetic technologies limited

GTG - Information a little old, but some points still relevant and interesting .....

  1. 103 Posts.
    lightbulb Created with Sketch. 1

    BREVAGen positions Genetic Technologies as a natural takeover target: In June 2013, NASDAQ listed Myriad Genetics received an adverse court ruling from the US Supreme Court regarding the company’s intellectual property. The ruling regarding Myriads hereditary breast cancer genetic test may have removed Myriad’s existing BRCA testing monopoly, although this is being disputed through the US courts. Myriad is understood to be looking to build its competitive advantage in the breast cancer testing arena by including a broad assessment of genetic markers in their tests. Myriad may consider acquiring Genetic Technologies in order to gain access to a novel, complementary test with growing sales that Key Opinion Leaders (KOL) recognise as having significant clinical utility.
watchlist Created with Sketch. Add GTG (ASX) to my watchlist
(20min delay)
Mkt cap ! $18.50M
Open High Low Value Volume
0.7¢ 0.7¢ 0.7¢ $1.62K 216K

Buyers (Bids)

No. Vol. Price($)
23 6735309 0.7¢

Sellers (Offers)

Price($) Vol. No.
0.8¢ 4351577 7
View Market Depth
Last update - 15.15pm 26/03/2019 (20 minute delay) ?
0.001 ( 0.00 %)
Open High Low Volume
0.7¢ 0.7¢ 0.7¢ 80000
Last updated 10.40am 26/03/2019 (live) ?
GTG (ASX) Chart
GET SUPPORT arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.